Jagath Reddy Junutula

Fremont, California, United States Contact Info
8K followers 500+ connections

Join to view profile

About

Twenty years of experience in oncology drug discovery and more than 25 years of…

Experience & Education

  • Aarvik Therapeutics Inc

View Jagath Reddy’s full experience

See their title, tenure and more.

or

By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.

Volunteer Experience

  • EPPIC Global Graphic

    Served as a Board Chairnan, President, Board Member, Treasurer, Assistant Treasurer and Volunteer

    EPPIC Global

    - 12 years

    Science and Technology

  • Science Gurus Graphic

    Board Chairman and Co-founder

    Science Gurus

    - Present 14 years 8 months

    Education

    www.sciencegurus.org

  • Boy Scouts of America Graphic

    Scoutmaster (2021) & ASM (2019-2020) at Troop273, Merit Badge Counselor (since 2019). Committee Chair for Troop2273 (2021-2023). Currently serving as a Scoutmaster for Troop2273 (Girls Troop).

    Boy Scouts of America

    Education

Publications

  • An anti-GDNF Family Receptor Alpha 1(GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.

    Mol Cancer Ther., 2018, 17, 638-649.

    See publication

  • CLT030, a Leukemic Stem Cell-Targeting CLL1 Antibody-Drug Conjugate for Treatment of Acute Myeloid Leukemia.

    Blood Advances, 2018, 2, 1738-1749.

    See publication

  • Design and synthesis of isoquinolidinobenzodiazepine dimers, a novel class of antibody-drug conjugate payload.

    ACS Med Chem Letters, 2018, 9, 56-60.

    See publication

  • High-Throughput Cysteine Scanning to Identify Stable Antibody Conjugation Sites for Maleimide and Disulfide-Based Linkers.

    Bioconjugate Chem., 2018, 29, 473-485.

  • Surface-functionalized Carrier-free Drug Nanorods for Leukemia.

    Advanced Therapeutics; Volume 1, Issue 2

    See publication

  • Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.

    Mol Cancer Ther., 2017, 16, 871-878.

    See publication

  • Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates

    Chemical Science, 2016,

  • Next-Generation Antibody-Drug Conjugates (ADCs) for Cancer Therapy

    ACS Medicinal Chemistry Letters, 2016, 7, 972-973

  • Antibody–Drug Conjugates: Design and Development of Trastuzumab Emtansine (T‐DM1)

    Successful Drug Discovery, 2015, 213-230

  • Cross-species gene expression analysis identifies a novel set of genes implicated in human insulin sensitivity

    npj Systems Biology and Applications; 2015, 1, 15010

  • Kinome Screen Identifies PFKFB3 and Glucose Metabolism as Important Regulators of the Insulin/Insulin-like Growth Factor (IGF)-1 Signaling Pathway

    J Biol Chem. 2015 Oct 23;290(43):25834-46

  • Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates

    Pharm Res. 2015 Jun;32(6):1884-93

  • Subcutaneous fat transplantation alleviates diet-induced glucose intolerance and inflammation in mice

    Diabetologia. 2015 Jul;58(7):1587-600

  • An improved and robust DNA immunization method to develop antibodies against extra-cellular loops of multi-transmembrane proteins

    mAbs 2014; 6:95 – 107

  • Development of a semi-automated high throughput transient transfection system

    J Biotechnol. 2014 Jun 20;180:10-6

  • Site-specific antibody drug conjugates for cancer therapy

    MAbs. 2014 Jan-Feb;6(1):34-45

    See publication

  • Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering

    J Med Chem. 2014 Oct 9;57(19):7890-9

    See publication

  • Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum

    Bioanalysis. 2013 May;5(9):1057-71

  • Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers

    Methods Mol Biol. 2013;1045:189-203

    See publication

  • Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies

    J Med Chem. 2013 Dec 12;56(23):9418-26

  • Impaired Akt phosphorylation in insulin-resistant human muscle is accompanied by selective and heterogenous down stream defects

    Diabetologia. 2013 Apr;56(4):875-85

  • Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells

    J Cell Sci. 2013 Oct 15;126(Pt 20):4647-58

  • Rac and Rab GTPases Dual Effector Nischarin Regulates Vesicle Maturation to Facilitate Survival of Intracellular Bacteria

    EMBO J. 2013 Mar 6;32(5):713-27

    See publication

  • Amplification and demultiplexing in the insulin regulated Akt pathway in adipocytes

    J Biol Chem. 2012 Feb 24;287(9):6128-38

  • Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

    Nat Biotechnol. 2012, 30(2):184-9

    See publication

  • Membrane Curvature Protein Exhibits Interdomain Flexibility and Binds a Small GTPase

    J Biol Chem. 2012 Nov 30;287(49):40996-1006

  • TBC1D13 is a RAB35 specific GAP that plays an important role in GLUT4 trafficking in adipocytes

    Traffic 2012 Oct;13(10):1429-41

  • Characterization of intact antibody-drug conjugates from plasma or serum in vitro and in vivo by affinity capture capillary LC-MS

    Analytical Biochemistry 2011, 412, 56-66

  • Emerging role of immunoPET in receptor targeted cancer therapy

    Curr Drug Deliv. 2011 Jan 1;8(1):70-8

  • Engineered trastuzumab-DM1 conjugate with an improved therapeutic index to target HER2-positive breast cancer

    Clin Cancer Res. 2010 Oct 1;16(19):4769-78

    See publication

  • FIP1/RCP binding to Golgin-97 regulates retrograde transport from recycling endosomes to trans-golgi network

    Mol Biol Cell 2010 Sep;21(17):3041-53

  • Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer

    Curr Opin Mol Ther. 2010 Apr;12(2):248-57

  • Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET

    Nucl Med Biol. 2010 37(3):289-97

  • Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin's lymphoma

    Blood 2009 Sep 24;114(13):2721-9

  • Rapid identification of reactive cysteine residues for site-specific labeling of antibody-fabs

    Journal of Immunological Methods 2008, 332, 41-52

  • Site-specific conjugation of cytotoxic drugs to antibodies substantially improves the therapeutic index

    Nature Biotechnol. 2008, 26 (8): 925-932

    See publication

  • Identification of Rab11 as a small GTPase binding protein for Evi5 oncogene

    Proc. Natl. Acad. Sci. 2007, 104(4):1236-41

  • Molecular characterization of Rab11-FIP3 binding to ARF GTPases

    Eur J. Cell Biol., 2007; 86, 417-431

  • Rab14 simulates phagosome-early endosome fusion and maintains Mycobacterium tuberculosis phagosome maturation arrest

    EMBO J. 2006 Nov 15;25(22):5250-9

  • Characterization of the role of the RabGAP AS160 in Insulin-regulated GLUT4 trafficking

    J. Biol. Chem. 2005, 280, 37803-37813

  • Class I FIPs, Rab11-Binding Proteins that regulate endocytic sorting and recycling

    Methods in Enzymology 2005, 403, 512-525

  • Structure of the Exo84-RBD:RalA complex: Insights into the mechanism of the Sec6/8 regulation by RalA

    EMBO J. 2005, 24, 2064-74

  • Molecular characterization of Rab11 interaction with members of the Family of Rab11- Interacting Proteins (FIPs)

    J. Biol Chem. 2004, 279, 33430-33437

  • Rab14 is involved in membrane trafficking between Golgi complex and endosomes

    Mol Biol Cell 2004, 15, 2218-2229

  • RCP-Rab11 complex regulates endocytic protein sorting and recycling to plasma membrane

    Mol Biol Cell 2004, 5, 3530-3541

  • Structural basis of the interaction between RalA and Sec5, a subunit of the Sec6/8 complex

    EMBO J. 2003, 22, 3267-3278

  • A discontiuous SNAP-25 C-terminal coil supports exocytosis

    J. Biol. Chem., 2001, 276, 28503-28508

  • Important role of the tetraloop region of 4.5S RNA in SRP binding to its receptor FtsY

    RNA 2001, 7(2), 293-301

  • Conformational changes in the bacterial SRP receptor FtsY upon binding of guanine nucleotides and SRP

    J. Mol. Biol. 2000, 295, 745-753

  • His230 of serine hydroxymethyltransferase facilitates the proton abstraction step in catalysis

    Eur. J. Biochem. 2000, 267, 1441-1446

  • Molecular insights into Signal Recognition Particle-dependent protein targeting

    Proc. Indian natn Sci Acad. (PINSA), 2000, B66, 145-166

  • Tetrameric Serine hydroxymethyltransferase: Insights into molecular organization, function and rational drug design

    Proceedings of the Fifth Royal Society-Unilever Indo-UK Forum in Materials Science and Engineering, The Royal Society, pp407-424, 2000

    Chapter in Supramolecular and Colloidal Structures in Biomaterials and Biosubstrates; Editors: Lal M, Lillford PJ, Naik VM and Prakash, V. Imperial College Press

    See publication

  • Asp-89: A critical residue in maintaining the oligomeric structure of sheep liver cytosolic serine hydroxymethyltransferase

    Biochem. J. 1999, 343, 257-263

  • Interaction of guanine nucleotides with signal recognition particle from Escherichia coli

    Biochemistry 1998, 37, 15408-15413

  • Assembly of Physalis mottle virus capsid protein in Escherichia coli and the role of amino and carboxy termini in the formation of the icosahedral particles

    J. Mol. Biol. 1997, 272, 541-552

  • Role of Arg-401 in the binding of carboxyl group of the substrate to cytosolic serine hydroxymethyltransferase

    Biochem. J. 1997, 327, 877-882

  • Role of His-134, His-147 and His-150 in the subunit assembly, cofactor binding and catalysis of cytosolic serine hydroxymethyltransferase

    J. Biol. Chem. 1997, 272, 24355-24362

  • The role of amino-terminal arm in the maintenance of the oligomeric structure of sheep liver cytosolic serine hydroxymethyltransferase

    Eur. J. Biochem. 1997, 247, 372-379

  • The role of lysine 256 in the structure and function of sheep liver recombinant serine hydroxymethyltransferase

    Acta Biochimica Polonica 1997, 44, 679-688

  • 3’ non-templated ‘A’ addition by Taq DNA polymerase: An advantage in the construction of single and double mutants

    Current science 1996, 71, 710-712

  • cDNA cloning, overexpression in Escherichia coli, purification and characterization of sheep liver cytosolic serine hydroxymethyltransferase

    Eur. J. Biochem. 1995, 230, 533-537

Patents

  • Cysteine engineered antibodies and conjugates

    Issued US 10,604,557

  • Anti-HER2 antibodies and immunoconjugates

    Issued US 10,556,966

  • Anti-CD79B antibodies and immunoconjugates and methods of use

    Issued US 10,544,218

  • Anti-CD79B antibodies and immunoconjugates and methods of use

    Issued US 10,494,432

  • Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers

    Issued US 10,350,218

  • Immunoconjugates comprising anti-HER2 antibodies and pyrrolobenzodiazepines

    Issued US 10,314,846

  • Anti-HER2 antibodies and immunoconjugates

    Issued US 10,179,820

  • Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates

    Issued US RE47,194

  • Cysteine engineered antibodies and conjugates

    Issued US 10,077,318

  • Isoquinolidinobenzodiazepines

    Issued US 9,974,864

  • Anti-CD79B antibodies and immunoconjugates and methods of use

    Issued US 9,896,506

  • Humanized anti-CD79b antibodies and immunoconjugates and methods of use

    Issued US 9,845,355

  • Compositions and methods for the diagnosis and treatment of tumor

    Issued US 9,580,514

  • Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers

    Filed US 20180177795

  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR HEMATOPOIETIC ORIGIN

    Filed US 20170362318

  • Anti-HER2 antibodies and immunoconjugates

    Issued US 9518118

  • Isoquinolidinobenzodiazepines

    Issued US 9504694

  • Humanized anti-CLL1 antibodies

    Filed US 20180355044

  • Cysteine-substituted immunoglobulins

    Filed US 20180312592

  • Anti-FcRH5 antibodies and immunoconjugates and methods of use

    Issued US 9,017,951

  • Cysteine engineered antibodies and conjugates

    Issued US 9,000,130

  • Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates

    Issued US 8,937,161

  • Anti-CD79B antibodies and immunoconjugates and methods of use

    Issued US 8,722,857

  • Anti-CD79B antibodies and immunoconjugates and methods of use

    Issued US 8,691,531

  • Anti-FcRH5 antibodies and immunoconjugates and methods of use

    Issued US 8,617,559

  • Anti-CD79B antibodies and immunoconjugates and methods of use

    Issued US 8,545,850

  • Anti-FcRH5 antibodies and immunoconjugates and methods of use

    Issued US 8,362,213

  • Anti-FcRH5 antibodies and immunoconjugates and methods of use

    Issued US 8,466,260

  • Cysteine engineered antibodies and conjugates

    Issued US 8,309,300

  • Anti-CD79B antibodies and immunoconjugates and methods of use

    Issued US 8,088,378

  • Cysteine engineered antibodies and conjugates

    Issued US 7,855,275

  • Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates

    Issued US 7,723,485

  • Cysteine Engineered Antibodies and Conjugates

    Issued US 7,521,541

  • Novel gene disruptions, composition and methods relating thereto

    Filed US 20080305106

  • Cysteine engineered antibodies and conjugates

    Filed US 20160130358

  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR

    Filed US 20150098946

  • NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO

    Filed US 20120030776

  • ALANINYL MAYTANSINOL ANTIBODY CONJUGATES

    Filed US 20120121615

  • Novel gene disruptions, compositions and methods relating thereto

    Filed US 20110252485

  • Novel gene disruptions, compositions and methods relating thereto

    Filed US 20110182883

  • Zirconium-radiolabeled, cysteine engineered antibody conjugates

    Filed US 20100111856

  • Novel Gene Disruptions, Compositions and Methods Relating Thereto

    Filed US 20090313707

  • Novel Gene Disruptions, Compositions and Methods Relating Thereto

    Filed US 20090142348

  • Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin

    Filed US 20090068178

Honors & Awards

  • Longstanding Contribution Award to Antibody Drug Conjugate Field

    World ADC Awards-Hanson Wade

  • CIRM Grant

    California Institute for Regenerative Medicine (CIRM)

    Served as a Project Investigator (PI) on Cellerant's CIRM grant ($6.8 millions) for the "Development of CLT030-ADC, a Leukemic Stem Cell Trageting Antibody-Drug-Conjugate, for Treatment of Acute Myeloid Leukemia".

  • SBIR Phase-II grant

    SBIR-NCI

    Received SBIR Phase-II grant from NCI for “Development of IL1RAP antibody-drug-conjugates”. The award grant is $1.5M and is serving as a Project Investigator (September 19, 2016-Septemebr 18, 2018)

  • Key papers published on THIOMAB technology featured in "Greatest Hits of 20 years of Nature Biotechnology Biomedical Research"

    Nature Biotechnology

    In a special 20-year issue, Nature Biotech highlighted key publications that described important technologies (along with their inventors) with significant impact on Biomedical Research. Here the link to the article (Nat.Biotechnol. 2016, March 10; 34(3):262-6).

    http://www.nature.com/nbt/journal/v34/n3/pdf/nbt.3509.pdf

  • Best ADC Platform-2015

    World ADC Summit

    THIOMAB Platform won a BEST ADC Platform Award at World ADC Summit-2015

  • Best Antibody Drug Conjugate (ADC) Publication during 2010-2014

    World ADC Summit

    Our paper won a BEST PUBLICATION award during 2010-2014 by World ADC Summit.

    Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
    Shen BQ, Xu K, et al. Junutula JR.
    Nat Biotechnol. 2012 Jan 22;30(2):184-9.

  • SBIR Phase-I grant

    NCI-SBIR

    Received and completed SBIR Phase-I grant from NCI for “Development of IL1RAP antibodies”. The award grant is $223,524 and served as a Project Investigator (September 12, 2014-August 11, 2015).

  • INSA Medal for Young Scientists for the Year 1998

    Indian National Science Academy

    Recipient of Indian National Science Academy (INSA)Young Scientist Award for conducting poineering research work in the Molecular Biology/Protein Engineering (academic year (1997-98) at the Nation-wide selection.

  • THE SHAMRAO KAIKINI MEDAL

    Indian Institute of Science

    THE SHAMRAO KAIKINI MEDAL (Best Thesis Award, 1997-1998) in the Biological and Chemical Sciences division from Indian Institute of Science, Bangalore, INDIA.

  • Editorial Board Membership

    mAbs, ACS MedChem Letters and Science Matters journals

    Member of Editorial Board for "mAbs, ACS MedChem Letters and Science Matters journals"

Languages

  • English

    Full professional proficiency

  • Telugu

    Full professional proficiency

  • Hindi

    Limited working proficiency

Organizations

  • Science Gurus

    Board Chairman

    - Present

    http://www.sciencegurus.org. Provides science-based education, training and mentor platforms that enable students to excel in Life Science careers.

  • EPPIC Global

    Board Chairman

    -

    EPPIC GLOBAL NETWORK: Powering Life Science Partnering and Mentoring. www.eppicglobal.org. Advancing the careers of life science professionals of Indian origin. Junutula JR, Raman P, Patel D, Butler H, Jayasuriya A. Nat Biotechnol. 2010 Jul;28(7):757-8.

View Jagath Reddy’s full profile

  • See who you know in common
  • Get introduced
  • Contact Jagath Reddy directly
Join to view full profile

Other similar profiles

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More

Add new skills with these courses

See all courses